Arbutus Biopharma (ABUS) stock forecast for 2026
Last update: 03-17-2022, 7:59Sector: Healthcare
The share price of Arbutus Biopharma Corp. (ABUS) now
What analysts predict:: $6.3
52-week high/low: $6.5 / $1.93
50/200 Day Moving Average: $2.573 / $3.017
This figure corresponds to the average price over the previous 50/200 days. For Arbutus Biopharma stocks, the 50-day moving average is the resistance level today.
For Arbutus Biopharma stocks, the 200-day moving average is the resistance level today.
Are you interested in Arbutus Biopharma stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Arbutus Biopharma stock price in 2026. How much will one Arbutus Biopharma share be worth in 2026?
Is it worth taking profit / loss on Arbutus Biopharma stock now or waiting? What are analysts' forecasts for Arbutus Biopharma stock?
We forecast Arbutus Biopharma stock performance using neural networks based on historical data on Arbutus Biopharma stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Arbutus Biopharma stock prediction results are shown below and presented as a graph, table and text information.
Arbutus Biopharma stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Arbutus Biopharma analysts is $6.3.
Today 200 Day Moving Average is the resistance level (3.017 $).
50 Day Moving Average is the resistance level (2.573 $).
Historical and forecast chart of Arbutus Biopharma stock
The chart below shows the historical price of Arbutus Biopharma stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Arbutus Biopharma stock price can be found in the table below.
Arbutus Biopharma (ABUS) Forecast for 2026
Arbutus Biopharma information and performance
Arbutus Biopharma Corporation, a biopharmaceutical company, is engaged in the discovery, development and commercialization of a drug for patients with chronic hepatitis B virus (HBV) infection in the United States. Its HBV product portfolio consists of AB-836, a capsid inhibitor that can inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is undergoing preclinical studies. The company is also developing RNAi preparations that use the RNA interference pathway, which allows a new approach to the treatment of diseases.
Arbutus Biopharma Address
100-8900 GLENLYON PARKWAY, BURNABY, BC, CA
Market Capitalization: 374 878 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -61 178 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 5.12
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 6.39
Enterprise Value (EV) /Revenue
EV To EBITDA: -3.439
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 149951000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Arbutus Biopharma price target for 2021 by month
Target values for the price of one Arbutus Biopharma share for Jan 2026.
Pessimistic target level: 2.40
Optimistic target level: 2.67
Target values for the price of one Arbutus Biopharma share for Feb 2026.
Pessimistic target level: 2.44
Optimistic target level: 2.74
Target values for the price of one Arbutus Biopharma share for Mar 2026.
Pessimistic target level: 2.61
Optimistic target level: 2.85
Target values for the price of one Arbutus Biopharma share for Apr 2026.
Pessimistic target level: 2.73
Optimistic target level: 2.91
Target values for the price of one Arbutus Biopharma share for May 2026.
Pessimistic target level: 2.51
Optimistic target level: 2.74
Target values for the price of one Arbutus Biopharma share for Jun 2026.
Pessimistic target level: 2.67
Optimistic target level: 2.84
Target values for the price of one Arbutus Biopharma share for Jul 2026.
Pessimistic target level: 2.60
Optimistic target level: 2.87
Target values for the price of one Arbutus Biopharma share for Aug 2026.
Pessimistic target level: 2.65
Optimistic target level: 2.82
Target values for the price of one Arbutus Biopharma share for Sep 2026.
Pessimistic target level: 2.50
Optimistic target level: 2.75
Target values for the price of one Arbutus Biopharma share for Oct 2026.
Pessimistic target level: 2.41
Optimistic target level: 2.67
Target values for the price of one Arbutus Biopharma share for Nov 2026.
Pessimistic target level: 2.42
Optimistic target level: 2.66
Target values for the price of one Arbutus Biopharma share for Dec 2026.
Pessimistic target level: 2.56
Optimistic target level: 2.86
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.